Skip to main content

Clinical Trials Using Vincristine

Review the clinical trials studying vincristine on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 70

A Study of Combination Chemotherapy for Patients with Newly Diagnosed DAWT and Relapsed FHWT
Status: Active
Location: 175 locations
Chemotherapy for the Treatment of Patients with Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
Status: Active
Location: 164 locations
Dinutuximab with Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children with Newly Diagnosed High Risk Neuroblastoma
Status: Active
Location: 151 locations
A Study Using Risk Factors to Determine Treatment for Children with Favorable Histology Wilms Tumors (FHWT)
Status: Active
Location: 136 locations
Inotuzumab Ozogamicin in Treating Younger Patients with B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Status: Active
Location: 137 locations
Testing the use of Daratumumab-Hyaluronidase in Persistent or Recurrent T Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/T-LBL) following Treatment with Chemotherapy
Status: Active
Location: 124 locations
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment with Blinatumomab for Children, Adolescents, and Young Adults with Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Status: Active
Location: 111 locations
A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss
Status: Active
Location: 98 locations
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants with Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Status: Active
Location: 98 locations
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma
Status: Active
Location: 70 locations
DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
Status: Active
Location: 25 locations
A Study to Give Treatment Inside the Eye to Treat Retinoblastoma
Status: Active
Location: 16 locations
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
Status: Active
Location: 15 locations
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
Status: Active
Location: 10 locations
Molecular and Clinical Risk Directed Therapy for Infants and Young Children with Newly Diagnosed Medulloblastoma
Status: Active
Location: 10 locations
A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma
Status: Active
Location: 10 locations
Mogamulizumab with DA-EPOCH for the Treatment of Aggressive T-cell Non-Hodgkin Lymphoma
Status: Active
Location: 9 locations
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
Status: Active
Location: 8 locations
Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
Status: Active
Location: 9 locations
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Status: Active
Location: 9 locations
Glucarpidase in Treating Patients with Central Nervous System B-Cell Non-Hodgkin Lymphoma
Status: Active
Location: 8 locations
Ibrutinib with or without Methotrexate, Rituximab, Vincristine, and Procarbazine in Treating Patients with Newly Diagnosed or Refractory/Recurrent Primary or Secondary Central Nervous System Lymphoma
Status: Active
Location: 7 locations
Atezolizumab in Combination with Chemotherapy in Treating Pediatric Patients with Relapsed or Refractory Solid Tumors, VITAS Trial
Status: Active
Location: 7 locations
Total Therapy for Infants with Acute Lymphoblastic Leukemia, The TINI 2 Study
Status: Active
Location: 7 locations
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Status: Active
Location: 5 locations